Spikevax (Original/ Omicron) COVID-19 Vaccine: Moderna’s mRNA booster for updated protection

Spikevax (Original/Omicron) is Moderna’s updated mRNA COVID-19 vaccine formulation, authorized as a booster dose for eligible adults and adolescents in the US and designed to broaden protection against circulating variants.

Responsible: ad hoc news Classics & Long-sellers Desk. Reviewed prior to publication on June 14, 2026 at 1:23 PM ET. Details in the imprint.

Spikevax (Original/Omicron) is Moderna’s updated mRNA COVID-19 vaccine formulation that targets both the ancestral SARS-CoV-2 strain and Omicron-lineage variants, positioning it as one of the company’s key long-running products in the US vaccination landscape. The vaccine has received authorization from the US Food and Drug Administration (FDA) as a booster dose for certain age groups, including adults and adolescents, reflecting health authorities’ ongoing focus on maintaining immunity against evolving variants. In the US, the formulation is typically supplied in multi-dose vials and is administered as an intramuscular injection by healthcare professionals in pharmacies, clinics, and physicians’ offices. For consumers, the updated Spikevax is intended to refresh protection after a primary vaccination series and earlier boosters, with guidance varying by age, prior vaccination status, and infection history.

What Spikevax (Original/Omicron) is designed to do

Spikevax is based on Moderna’s mRNA platform, in which a small piece of genetic code instructs cells to produce a version of the coronavirus spike protein, triggering an immune response without using live virus. The Original/Omicron formulation is a so-called bivalent or variant-updated vaccine, combining mRNA sequences that encode the spike protein from the ancestral strain and from Omicron lineage variants, with the goal of broadening neutralizing antibody responses across currently circulating strains. According to FDA briefing materials and public health summaries, laboratory data have shown that these updated mRNA vaccines can increase antibody levels against Omicron sublineages compared with earlier, original-strain-only formulations, though real-world effectiveness depends on factors such as age, timing of doses, and emerging variants. For US patients, Spikevax is typically given as a single booster dose at least several months after the last COVID-19 vaccine dose, with detailed schedules set out in CDC vaccination recommendations.

As with Moderna’s earlier COVID-19 vaccine formulations, Spikevax (Original/Omicron) is supplied as a sterile suspension in vials that require cold-chain storage and specific handling conditions before administration. Healthcare providers are instructed to store unopened vials frozen or refrigerated within defined temperature ranges and to use each vial within a set time window after puncture, to ensure potency and safety as outlined in the product’s prescribing information. Commonly reported side effects of Spikevax include injection-site pain, fatigue, headache, muscle aches, and chills, which typically resolve within a few days, similar to earlier mRNA COVID-19 vaccines. Post-authorization safety monitoring has also identified rare risks such as myocarditis and pericarditis, particularly in younger males, leading regulators to include warnings in the product labeling and to emphasize that individuals and healthcare professionals weigh these risks against the benefits of protection from COVID-19. These safety findings are monitored through ongoing pharmacovigilance systems, including vaccine safety databases and observational studies coordinated by health agencies.

In the US market, Spikevax (Original/Omicron) is available through multiple channels, including national pharmacy chains, hospitals, community health centers, and physician practices that participate in federal or state vaccination programs. Since the transition of COVID-19 vaccines to commercial distribution, Moderna has entered supply and reimbursement arrangements with US government programs and private insurers, allowing many eligible individuals to receive booster doses at low or no out-of-pocket cost depending on coverage. The list price for Moderna’s updated COVID-19 vaccines in the commercial market has been reported in the range of roughly $100 to $130 per dose, although the actual cost to consumers varies based on insurance, government programs, and provider pricing. For uninsured or underinsured people, federal initiatives and manufacturer support programs have aimed to maintain access to updated COVID-19 shots, including Spikevax, without direct charges to patients in many scenarios.

How Spikevax fits into Moderna’s vaccine portfolio

Spikevax (Original/Omicron) remains a central product within Moderna’s vaccine lineup, representing one of the first large-scale commercial applications of its mRNA technology and forming the backbone of its revenue during the pandemic years. While overall demand for COVID-19 boosters has moderated compared with the initial vaccination campaigns, updated formulations like Spikevax continue to play a role in protecting higher-risk populations, including older adults, people with certain underlying medical conditions, and healthcare workers. Moderna has highlighted in investor presentations that it is evolving Spikevax into a seasonal respiratory vaccine offering, with ongoing development of next-generation COVID-19 vaccines and potential combination shots that may pair COVID-19 antigens with influenza or respiratory syncytial virus (RSV) components. These pipeline efforts are designed to leverage the same mRNA platform that underpins Spikevax, allowing relatively rapid updates of antigen sequences in response to variant evolution and seasonal virus patterns.

Regulatory agencies, including the FDA and global counterparts, periodically review variant composition recommendations for COVID-19 vaccines, and Moderna adapts its Spikevax formulations accordingly. For example, prior variant-updated versions have targeted specific Omicron subvariants, based on the World Health Organization and national advisory group recommendations. This iterative update process is similar in concept to the annual strain selection for influenza vaccines, but with timelines and manufacturing scaled to the mRNA platform’s capabilities for rapid production. For providers and patients, that means the Spikevax name may cover slightly different antigen compositions over time, all built on the same core mRNA technology and manufacturing infrastructure. Public health communication materials typically specify the exact variant content and season or update cycle to help avoid confusion between earlier and current Spikevax doses.

For shoppers evaluating healthcare decisions, understanding where Spikevax (Original/Omicron) sits in Moderna’s broader portfolio can help contextualize its role among other respiratory and infectious disease candidates under development. Moderna’s disclosed pipeline includes mRNA-based vaccines targeting flu, RSV, cytomegalovirus (CMV), and other pathogens, many of which are in active clinical trials, and the company has stated that experience gained from the development and large-scale deployment of Spikevax informs its approach to these newer products. Investors following the company’s progress often view the performance of Spikevax, including updated formulations like Original/Omicron, as a reference point for commercial execution, regulatory interactions, and the robustness of Moderna’s manufacturing network. For now, Spikevax continues to act as a bridge between the initial emergency-pandemic phase of COVID-19 immunization and a more routine, seasonal vaccination model that Moderna aims to participate in alongside other major vaccine manufacturers. Shares of Moderna Inc. (US60770K1079, ticker MRNA) traded at $XX.XX on Nasdaq on June 13, 2026.

Snapshot: Spikevax (Original/Omicron) at a glance

• Product: Spikevax (Original/Omicron) COVID-19 Vaccine
• Manufacturer: Moderna Inc.
• Category: Classic/Long-seller
• Launch date: Variant-updated formulations authorized in the US during the Omicron phase of the COVID-19 pandemic, following initial Spikevax authorizations in 2020-2021.
• MSRP / Price: Commercial list pricing for updated Moderna COVID-19 vaccines has been reported around $100-$130 per dose in the US, with patient costs depending on insurance and assistance programs.
• Availability: Administered in the US through pharmacies, clinics, hospitals, and physician offices participating in COVID-19 vaccination programs.
• Target audience: Adults and eligible adolescents recommended by US health authorities for an updated COVID-19 booster, especially higher-risk groups.
• Key feature / USP: mRNA-based updated formulation designed to broaden immune protection against both ancestral SARS-CoV-2 and Omicron-lineage variants.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.